GlassScriptPhysician profile
Amir Ali Malik
NPI 1386749505
$2,456.41
in general payments reported to CMS, 2019-2025
20 companies · $317 in 2025
The $317 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $746 · 2020: $296 · 2021: $360 · 2022: $226 · 2023: $362 · 2024: $149 · 2025: $317.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $784 · Education: $44.89.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $783.81 |
| Education | $44.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $733.00 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $548.44 | 2020-2025 | Lokelma, Farxiga |
| Horizon Therapeutics Plc | $194.55 | 2020-2021 | |
| Opko Pharmaceuticals, LLC | $168.01 | 2019-2023 | Rayaldee |
| Vantive US Healthcare LLC | $132.14 | 2025 | Renal - Pd |
| Vifor Pharma, INC. | $119.91 | 2024-2025 | Veltassa |
| Travere Therapeutics, INC. | $93.92 | 2023-2025 | |
| Mallinckrodt Enterprises LLC | $88.23 | 2019 | |
| Mallinckrodt Hospital Products INC. | $81.99 | 2020-2022 | |
| Fresenius USA Marketing, INC. | $54.16 | 2019-2020 | |
| Amgen INC. | $36.52 | 2019 | |
| Dexcom, INC. | $31.98 | 2024 | Dexcom G6 Transmitter |
| Otsuka America Pharmaceutical, INC. | $28.69 | 2023 | Jynarque |
| Ethicon US, LLC | $28.11 | 2024 | Dermabond Prineo, Vistaseal, Stratafix |
| Abbvie INC. | $20.77 | 2023 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $20.30 | 2023 | Injectafer |
| Calliditas Therapeutics US INC. | $19.56 | 2023 | Tarpeyo |
| Bayer Healthcare Pharmaceuticals INC. | $19.48 | 2022 | |
| Akebia Therapeutics INC | $18.55 | 2019 | |
| Novo Nordisk INC | $18.10 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amir Malik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.